Các khuôn mẫu mới trong quản lý viêm gan do rượu: một bài tổng quan

Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;2009(360):2758–2769 O’Shea RS, Dasarathy S, McCullough AJ. The Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010;2010:307–328 Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of person with harmful alcohol consumption-II. Addiction 1993;1993(88):791–804 Childer RE, Joseph AH. Diagnosis of alcoholic hepatitis liver disease. Clin Liver Dis 2016;2016(20):457–471 Heuman DM, Hung PD. Alcoholic hepatitis. Drug and disease. Gastroenterology. http://emedicine.medscape.com/article/170539-overview Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology 2016;150(4):785–790 Kato M, Kato S, Horiuchi S, Nagai K, Horie Y, Hayashi K. Mallory bodies in hepatocytes of alcoholic liver disease and primary biliary cirrhosis contain-(carboxymethyl) lysine-modified cytokeratin, but not those in hepatic carcinoma cells. Yonago Acta Med 2006;49:83–92 EASL Clinical Practical Guidelines. Management of alcoholic liver disease. J Hepatol 2012;57:399–420 Hanouneh IA, Zein NN, Cikach F, Dababneh L, Grove D, Alkhouri N, et al. The breath prints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol 2014; 12(3): 516–523 Sidhu SS, Goyal O, Singla P, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE Trial). Dig Dis Sci 2012;57(6):1664–1671 Singh V, Sharma KA, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;2014(109):1417–1423 Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;2008(103):2747–2756 O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010;2010(105):14–32 Arteel GE. Build a better mouse model, and the world will beat a path to your door. Hepatology 2013;58(5):1526–1528 Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58(5):949–955 Zhong W, McClain CJ, Cave M, Kang YJ, Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol 2010;298(5):G625–G633 Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3(3): 178–185 Dunn W, Shah VH. Pathogenesis of alcoholic liver disease. Clin Liver Dis 2016;2016(20):445–456 Alpert L, Hart J. The pathology of alcoholic liver disease. Clin Liver Dis 2016;2016(20):473–489 Vessey Carina J, Pauline M, De La Hall M. Hepatic stem cells: a review. Pathology 2001;33:130–141 Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Rojo AD, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146(5):1231–1239 Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O’Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology 2015;149(2): 398–406 Rachakonda V, Gabbert C, Raina A, Li H, Malik S, DeLany JP, et al. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin Exp Res 2014;2014(38):2712–2721 Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311:1889 Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2015;2005(6):2103–2115 Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011; 4(1): 63–81 Kaisdotter A, Kron J, Castren M, Athlin AM, Hok B, Wiklund L. Assessment of the breath alcohol concentration in emergency care patients with different level of consciousness. Scand J Trauma Resusc Emerg Med 2015; 23:11 Piano SM, Rosi S, Cavallin M, Romano A, Gola E, Marchioro L, et al. Urinary ethyl glucuronide improves the detection of alcohol consumption in liver transplantation candidates and recipients. Hepatology 2012;56:977A Sterneck MA, Staufer K, Schulz KH, Nashan B. Ethyl glucuronide determination in hair for evaluation of long-term alcohol abstention in liver transplant candidates. Hepatology 2012;56:493A Mezey E. Interaction between alcohol and nutrition in the pathogenesis of alcoholic liver disease. Semin Liver Dis 1991;1991(11):340–348 Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984;1984(76):211–222 Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016;2016(150):903–910 Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: sarcopenia in cirrhosis-aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther 2016;43(7):765–777 Montano-Loza AJ, Meza-Junco J, Prado CMM, Tandon P, Bain VG, Ma M, et al. New cutoff values for sarcopenia for predicting 6-month mortality in cirrhotic patients. J Hepatol 2013;58(Suppl):S95 Puri P, Thurz M. Intensive enteral nutrition in alcoholic hepatitis: more food for thought. Gastroenterology 2016; 150(4): 803–805 Taieb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000;2000(32):579–586 Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;1990(172):391–394 Thursz M, Richardson P, Allison M, Austin A, Bowers M, Christopher P, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;2015(372):1619–1628 Thursz MR, Louvet A, Kim DJ, Labreuche J, Atkinson SR, Sidhu S, et al. Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients. In Paper presented at AASLD Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2015;2000(119):1637–1648 Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS, Sood A. Pentoxiphylline in severe alcoholic hepatitis: a prospective, randomized trial. J Assoc Phys India 2012;2011(69):20–22 Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; CD007339 Louvet A, Diaz E, Dharancy S. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;2008(48):465–470 Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis. A randomized clinical trial. JAMA 2013;310(10):1033–1041 Nguyen-khac E, Theevenot T, Benferhat S, Goria O, Chatelain D, Tramier B, et al. Glucocorticoids plus N-acetyl cysteine in severe alcoholic hepatitis. N Engl J Med 2011;365:1781–1789 Centre Hospitalier Universitaire, Amiens. Treatment of Severe Alcoholic Hepatitis with Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone (HAA-NAC). https://clinicaltrials.gov/ct2/show/NCT00863785 Higuera-de la Tijera F, Servin-Caamano AI, Cruz-Herrera J, Serralde-Zuniga AE, Abdo-Francis JM, Gutierrez-Reyes G, et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Ann Hepatol 2014;13(3):343–352 Higuera-de la Tijera F, Servin-Caamano AL, Serralde-Zuniga AE, Herrera JC, Torres EP, Abdo-Francis AM, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol 2015; 21(16): 4975–4985 Naveau S, Chollet-Martin S, Dharancy S, Jouet P, Piquet MA, Davion T, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;2004(39):1390–1397 Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis (review). Cochrane Database Syst Rev 2001;(3):CD002148 RambaldiAL, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2003;(1):CD003045 Mato JM, Camara J, Fernandez J, Caballeria L, Coll S, Caballero A, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;1999(30):1081–1089 Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987;1987(317):1421–1427 Morris JML, Dickson S, Neilson M, Hodgins P, Forrest EH. Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series. Eur J Gastroenterol Hepatol 2010;22(4):457–460 Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003(54):24–31 Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;2007(45):1348–1354 Dubuquoy L, Louvet A, Lassailly G, Truant S, Boleslawski E, Artru F, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 2015;2015(64):1949–1960 Tato CM, Cua DJ. SnapShot: cytokines IV. Cell 2008; 132:1062 Rolas L, Makhezer N, Hadjoudj S, El-Benna J, Djerdjouri B, Elkrief L, et al. Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. Hepatology 2013;2013(57):1163–1671 Moreau R, Rautou PE. G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol 2014;2014(109):1424–1426 Kim DJ. Efficacy and Safety of Granulocyte-Colony Stimulating Factor in Patients with Severe Alcoholic Hepatitis with Null or Partial Response to Steroid: A Randomized, Double-Blind, Placebo-Controlled, Nationwide Multi-Center Study. https://clinicaltrials.gov/ct2/show/NCT02442180 Shasthry SM. Efficacy of G-CSF in the Management of Steroid Non-Responsive Severe Alcoholic Hepatitis. A Double Blind Randomized Control Trial. https://clinicaltrials.gov/ct2/show/NCT01820208 Struff WG, Sprotte G. Bovine colostrum as a biologic in clinical medicine: a review—Part II. Int J Clin Pharmacol Ther 2008;46:211–225 Kelly GS. Bovine colostrums: a review of clinical uses. Altern Med Rev 2003;8:378–394 Sidhu S, Goyal O, Kishore H. Corticosteroids and Bovine Colostrum in Treatment of Alcoholic Hepatitis ‘In Extremis’: A Pilot Study. In Paper Presented at Emerging Trends Conference in Alcohol Hepatitis. JW Marriott Miami, 22–23 January 2016 Virginia Commonwealth University. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Safety and Efficacy of IMM 124-E for Patients with Severe Alcoholic Hepatitis (TREAT). https://clinicaltrials.gov/ct2/show/NCT01968382 Institute of Liver and Biliary Sciences, India. Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis. https://clinicaltrials.gov/ct2/show/NCT02458079 Philips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, et al. Healthy donor fecal microbiota transplantation in steroid ineligible severe alcoholic hepatitis—a pilot study. Clin Gastroenterol Hepatol 2016;. doi:10.1016/j.cgh.2016.10.029 Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis. https://clinicaltrials.gov/ct2/show/NCT01809132 University Hospital, Lille. Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated with Prednisolone (AntibioCor). https://clinicaltrials.gov/ct2/show/NCT02281929 University of Texas South Western Medical Centre. Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis (NTAH-Mod).https://clinicaltrials.gov/ct2/show/NCT01922895 Hospital Universitari Vall d’Hebron Research Institute. Effects of Rifaximin in Patients with Acute Alcoholic Hepatitis (RIFA-AAH). https://clinicaltrials.gov/ct2/show/NCT02116556 Helsinki University. Randomised Open-Label Multicentre Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis. https://clinicaltrials.gov/ct2/show/NCT02326103 Conatus Pharmaceuticals Inc. Study of IDN-6556 in Patients with Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy (AH). https://clinicaltrials.gov/ct2/show/NCT01912404. Mayo Clinic. Use of F-652 in Patients with Alcoholic Hepatitis (TREAT 008). https://clinicaltrials.gov/ct2/show/NCT02655510. Indiana University. Trial of Obeticholic Acid in Patients with Moderately Severe Alcoholic Hepatitis (TREAT 002). https://clinicaltrials.gov/ct2/show/NCT02039219. Gilead Sciences. GS-4997 in Combination with Prednisolone Versus Prednisolone Alone in Participants with Severe Alcoholic Hepatitis. https://clinicaltrials.gov/ct2/show/NCT02854631. Brown RS Jr. Transplantation for alcoholic hepatitis time to rethink the 6-month rule. N Engl J Med 2011;2011(365):1836–1838 Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;2011(365):1790–1800